Does Rallies show live market data for BCAX?

Rallies combines live market context with ticker research for BCAX, including charts, news, financials, analyst data, institutional holdings, politician trades, insider activity, and AI research where available.

BCAX (Bicara Therapeutics Inc. Common Stock) Stock Analysis

Bicara Therapeutics Inc. Common Stock (BCAX) is a publicly traded Healthcare sector company. As of May 21, 2026, BCAX trades at $20.11 with a market cap of $1.27B and a P/E ratio of -8.10. BCAX moved +2.05% today. Year to date, BCAX is +26.82%; over the trailing twelve months it is +35.84%. Its 52-week range spans $7.80 to $28.09. Analyst consensus is strong buy with an average price target of $30.99. Rallies surfaces BCAX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What is the latest BCAX stock research?

Bicara Therapeutics Inc. Common Stock (BCAX) research on Rallies includes live charts, financials, analyst ratings, hedge fund holdings, politician trades, insider activity, news, AI research, and community context. BCAX moved +2.05% today. Analyst consensus is strong buy.

BCAX Key Metrics

Key financial metrics for BCAX
Metric	Value
Price	$20.11
Market Cap	$1.27B
P/E Ratio	-8.10
EPS	$-2.52
Dividend Yield	0.00%
52-Week High	$28.09
52-Week Low	$7.80
Volume	4.29K
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-137.95M
Gross Margin	0.00%

Latest BCAX News

Bicara posts $8.3M Q1 net loss, advances BT-11 Phase 1b/2a and BT-12 IND — May 12, 2026
Bicara Secures $161.8M, Holds $539.8M Cash, Q3 Ficerafusp Combo Trial — May 11, 2026
Bicara Therapeutics Launches Phase 3 FORTIFI-HN01 Trial and Raises $161.8M — Mar 30, 2026
Bicara’s Ficera Achieves 54% ORR, BofA Initiates Buy with $35 — Mar 25, 2026
Bicara Sets FORTIFY Trial at 1,500 mg Weekly Dose Versus Pembrolizumab, Mid-2027 Readout Target — Mar 6, 2026

Recent BCAX Insider Trades

Cohlhepp Ryan sold 8.00K (~$162.34K) on May 15, 2026.
Cohlhepp Ryan sold 4.50K (~$91.31K) on May 15, 2026.
Raben David sold 5.50K (~$125.83K) on Apr 27, 2026.

BCAX Analyst Consensus

11 analysts cover BCAX: 0 strong buy, 9 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $30.99.

Common questions about BCAX

What can I research for BCAX on Rallies?: Bicara Therapeutics Inc. Common Stock (BCAX) research on Rallies includes live charts, financials, analyst ratings, hedge fund holdings, politician trades, insider activity, news, AI research, and community context. BCAX moved +2.05% today. Analyst consensus is strong buy.
Does Rallies show live market data for BCAX?: Rallies combines live market context with ticker research for BCAX, including charts, news, financials, analyst data, institutional holdings, politician trades, insider activity, and AI research where available.